Home page |Editorial  board | About the Journal   | Instructions for Authors | Peer Review Policy | Clinical and Experimental Work Code |   Contact  |
 

Acta Medica Medianae
Vol. 40
No 4, 2001
UDK 61
YU ISSN 0365-4478

 




Contact:
Gordana ZLATANOVIĆ
Clinic for Eye Diseases of the Clinic Center, Niš

 

 

 

MODERN THERAPY OF THE RETINA VASCULITIS

 

Gordana ZLATANOVIĆ, Gordana STANKOVIĆ-BABIĆ, Predrag JOVANOVIĆ, Milena VUJANOVIĆ i Šonja ŽIVKOVIĆ

 

Clinic for Eye Diseases of the Clinic Center, Niš

 

The therapy of the retina vasculitis is very complex. The basic therapeutic principle is to find a balance between the medicament toxicity and the seriousness of the retina disease. In easy forms of the disease, with a good seeing shaipness, it is sufficient to observe a patient with no therapy at all. For serious diseases the medicaments to be chosen are corticosteroids. If there is no favorable response to the corticosteroid therapy, in bilateral serious forms of the retina vasculitis and especially in the Behchet disease, a therapy with cytostatics is applied. The most frequently used are cyclophosphamide and chlorambucil. In the last few years s highly-selective immunosuppressive cyclosporine A in small doses is used combined with corticosteroids. A new approach to suppressing the auto-aggressive Ag-specific T-cells and their pro-inflammatory products implies the use of a new generation of immunosuppressive medicaments such as tacrolimus (FK 506) and T-cell specific antimetabolites. More recently the desensibilization by the retina S-antigen has been used in the therapy of the retina vasculitis.

 

Key words: retina vasculitis, corticosteroids, cytostatics, cyclosporine A, tacromilus, desensibilization by the retina S-antigen